{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:31:09Z","timestamp":1790101869471,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1F1A1072795"],"award-info":[{"award-number":["2020R1F1A1072795"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the long-term outcomes of ranibizumab (RBZ) vs. aflibercept (AFL) in treatment-na\u00efve eyes with typical neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). This multicenter, retrospective, matched-cohort\u00a0analysis was conducted on data\u00a0 up to\u00a04\u00a0years\u00a0of follow-ups. The primary outcome was the visual acuity (VA) change from baseline. The secondary outcomes included the number of injections, proportion of eyes without a yearly injection, and the number of eyes with treatment switching. Subgroup analyses were performed for typical nAMD and PCV. Typical nAMD was defined as nAMD other than PCV. We included VA-matched\u00a0215 eyes of 209 patients (131 and 84 eyes with RBZ and AFL, respectively). The crude mean VA changes from baseline were\u2009+\u20096.7 vs.\u2009+\u20092.6,\u2009+\u20092.1 vs.\u2009\u2212\u20090.4,\u2009\u2212\u20091.3 vs.\u2009\u2212\u20091.8, and\u2009\u2212\u20092.2 vs. \u2212 5.0 letters in the RBZ and AFL groups, at 1, 2, 3, and 4 years, respectively (p\u2009&gt;\u20090.05). The adjusted predicted VA by linear mixed model, proportion of eyes stratified by VA, and the survival curve for significant vision loss were comparable during the 4-year\u00a0follow-up (p\u2009&gt;\u20090.05). The mean number of injections were similar between the RBZ and AFL groups (2.9 vs. 3.0, respectively, p\u2009=\u20090.692). The subgroup analysis for typical nAMD and PCV showed similar results between the groups. The visual outcomes did not differ between RBZ and AFL during 4 years with comparable numbers of injections. Our study reflects the long-term, real-world clinical practice and treatment pattern of two treatments for typical nAMD and PCV.<\/jats:p>","DOI":"10.1038\/s41598-021-93899-x","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T10:03:33Z","timestamp":1626429813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy"],"prefix":"10.1038","volume":"11","author":[{"given":"Ki Won","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Hyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"93899_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell, P., Liew, G., Gopinath, B. & Wong, T. Y. Age-related macular degeneration. Lancet 392, 1147\u20131159. https:\/\/doi.org\/10.1016\/S0140-6736(18)31550-2 (2018).","journal-title":"Lancet"},{"key":"93899_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/jcm4020343","volume":"4","author":"Y Yonekawa","year":"2015","unstructured":"Yonekawa, Y., Miller, J. W. & Kim, I. K. Age-related macular degeneration: Advances in management and diagnosis. J. Clin. Med. 4, 343\u2013359. https:\/\/doi.org\/10.3390\/jcm4020343 (2015).","journal-title":"J. Clin. Med."},{"key":"93899_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown, D. M. et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116, 57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018 (2009).","journal-title":"Ophthalmology"},{"key":"93899_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481 (2006).","journal-title":"N. Engl. J. Med."},{"key":"93899_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth, U. et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies. Ophthalmology 121, 193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011 (2014).","journal-title":"Ophthalmology"},{"key":"93899_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006 (2012).","journal-title":"Ophthalmology"},{"key":"93899_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani, G. A. et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am. J. Ophthalmol. 148, 43\u201358. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.024 (2009).","journal-title":"Am. J. Ophthalmol."},{"key":"93899_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva, R. et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: Results with ranibizumab from the TREND study. Ophthalmology 125, 57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.014 (2018).","journal-title":"Ophthalmology"},{"key":"93899_CR9","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","volume":"122","author":"CC Wykoff","year":"2015","unstructured":"Wykoff, C. C. et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122, 2514\u20132522. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.009 (2015).","journal-title":"Ophthalmology"},{"key":"93899_CR10","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1016\/j.ophtha.2016.08.016","volume":"123","author":"MC Gillies","year":"2016","unstructured":"Gillies, M. C. et al. Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration: Data from an observational study. Ophthalmology 123, 2545\u20132553. https:\/\/doi.org\/10.1016\/j.ophtha.2016.08.016 (2016).","journal-title":"Ophthalmology"},{"key":"93899_CR11","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/eye.2017.143","volume":"31","author":"A Lotery","year":"2017","unstructured":"Lotery, A., Griner, R., Ferreira, A., Milnes, F. & Dugel, P. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye (Lond.) 31, 1697\u20131706. https:\/\/doi.org\/10.1038\/eye.2017.143 (2017).","journal-title":"Eye (Lond.)"},{"key":"93899_CR12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2019.10.006","volume":"127","author":"S Bhandari","year":"2020","unstructured":"Bhandari, S. et al. Treatment outcomes of ranibizumab versus aflibercept for neovascular age-related macular degeneration: Data from the fight retinal blindness! registry. Ophthalmology 127, 369\u2013376. https:\/\/doi.org\/10.1016\/j.ophtha.2019.10.006 (2020).","journal-title":"Ophthalmology"},{"key":"93899_CR13","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","volume":"125","author":"P Rao","year":"2018","unstructured":"Rao, P. et al. Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry. Ophthalmology 125, 522\u2013528. https:\/\/doi.org\/10.1016\/j.ophtha.2017.10.010 (2018).","journal-title":"Ophthalmology"},{"key":"93899_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong, C. W. et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog. Retin Eye Res. 53, 107\u2013139. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.04.002 (2016).","journal-title":"Prog. Retin Eye Res."},{"key":"93899_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000431000","volume":"234","author":"W Matsumiya","year":"2015","unstructured":"Matsumiya, W. et al. Comparison of the effectiveness and prognostic factors of intravitreal ranibizumab between typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 24 months of follow-up. Ophthalmologica 234, 33\u201339. https:\/\/doi.org\/10.1159\/000431000 (2015).","journal-title":"Ophthalmologica"},{"key":"93899_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.oret.2018.11.003","volume":"3","author":"KY Chong Teo","year":"2019","unstructured":"Chong Teo, K. Y. et al. A multicountry comparison of real-world management and outcomes of polypoidal choroidal vasculopathy: Fight retinal blindness! cohort. Ophthalmol. Retina 3, 220\u2013229. https:\/\/doi.org\/10.1016\/j.oret.2018.11.003 (2019).","journal-title":"Ophthalmol. Retina"},{"key":"93899_CR17","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1038\/s41598-019-39995-5","volume":"9","author":"K Nishikawa","year":"2019","unstructured":"Nishikawa, K. et al. Four-year outcome of aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Sci. Rep. 9, 3620. https:\/\/doi.org\/10.1038\/s41598-019-39995-5 (2019).","journal-title":"Sci. Rep."},{"key":"93899_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bjophthalmol-2014-305674","volume":"99","author":"CS Tan","year":"2015","unstructured":"Tan, C. S. et al. EVEREST study report 2: Imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 99, 624\u2013628. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305674 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"93899_CR19","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","volume":"122","author":"JJ Arnold","year":"2015","unstructured":"Arnold, J. J. et al. Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology 122, 1212\u20131219. https:\/\/doi.org\/10.1016\/j.ophtha.2015.02.009 (2015).","journal-title":"Ophthalmology"},{"key":"93899_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz, F. G. et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br. J. Ophthalmol. 99, 220\u2013226. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327 (2015).","journal-title":"Br. J. Ophthalmol."},{"key":"93899_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla, T. A. et al. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol. Retina 2, 645\u2013653. https:\/\/doi.org\/10.1016\/j.oret.2018.01.006 (2018).","journal-title":"Ophthalmol. Retina"},{"key":"93899_CR22","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha, S. et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 120, 2292\u20132299. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046 (2013).","journal-title":"Ophthalmology"},{"key":"93899_CR23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","unstructured":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: Multicenter study of 92976 Ranibizumab injections: Report 1: Visual acuity. Ophthalmology 121, 1092\u20131101. https:\/\/doi.org\/10.1016\/j.ophtha.2013.11.031 (2014).","journal-title":"Ophthalmology"},{"key":"93899_CR24","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00417-019-04361-8","volume":"257","author":"I Wada","year":"2019","unstructured":"Wada, I. et al. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefes Arch. Clin. Exp. Ophthalmol. 257, 1411\u20131418. https:\/\/doi.org\/10.1007\/s00417-019-04361-8 (2019).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"93899_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ajo.2016.09.038","volume":"174","author":"M Eleftheriadou","year":"2017","unstructured":"Eleftheriadou, M. et al. Long-term outcomes of aflibercept treatment for neovascular age-related macular degeneration in a clinical setting. Am. J. Ophthalmol. 174, 160\u2013168. https:\/\/doi.org\/10.1016\/j.ajo.2016.09.038 (2017).","journal-title":"Am. J. Ophthalmol."},{"key":"93899_CR26","doi-asserted-by":"publisher","first-page":"7465270","DOI":"10.1155\/2020\/7465270","volume":"2020","author":"Y Gayadine-Harricham","year":"2020","unstructured":"Gayadine-Harricham, Y., Rufin, V., Law-Koune, S. & Tran, T. H. C. Four-year outcome of aflibercept treatment-naive patients for neovascular age-related macular degeneration: Evidence from a clinical setting. J. Ophthalmol. 2020, 7465270. https:\/\/doi.org\/10.1155\/2020\/7465270 (2020).","journal-title":"J. Ophthalmol."},{"key":"93899_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120938565","author":"M Lukic","year":"2020","unstructured":"Lukic, M. et al. Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting. Eur. J. Ophthalmol. https:\/\/doi.org\/10.1177\/1120672120938565 (2020).","journal-title":"Eur. J. Ophthalmol."},{"key":"93899_CR28","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"The Comparison of Age-Related Macular Degeneration Treatments Trials Research Group","year":"2016","unstructured":"The Comparison of Age-Related Macular Degeneration Treatments Trials Research Group et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: Comparison of age-related macular degeneration treatments trials research. Ophthalmology 123, 1751\u20131761. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.045 (2016).","journal-title":"Ophthalmology"},{"key":"93899_CR29","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies, M. C. et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: Data from an observational study. Ophthalmology 122, 1837\u20131845. https:\/\/doi.org\/10.1016\/j.ophtha.2015.05.010 (2015).","journal-title":"Ophthalmology"},{"key":"93899_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ophtha.2014.11.018","volume":"122","author":"MC Peden","year":"2015","unstructured":"Peden, M. C., Suner, I. J., Hammer, M. E. & Grizzard, W. S. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology 122, 803\u2013808. https:\/\/doi.org\/10.1016\/j.ophtha.2014.11.018 (2015).","journal-title":"Ophthalmology"},{"key":"93899_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/aos.14183","volume":"98","author":"T Brynskov","year":"2020","unstructured":"Brynskov, T., Munch, I. C., Larsen, T. M., Erngaard, L. & Sorensen, T. L. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol. 98, 132\u2013138. https:\/\/doi.org\/10.1111\/aos.14183 (2020).","journal-title":"Acta Ophthalmol."},{"key":"93899_CR32","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.2147\/OPTH.S218378","volume":"13","author":"F Horner","year":"2019","unstructured":"Horner, F. et al. Real-world visual and clinical outcomes for patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: An 8-year observational cohort (AMD8). Clin. Ophthalmol. 13, 2461\u20132467. https:\/\/doi.org\/10.2147\/OPTH.S218378 (2019).","journal-title":"Clin. Ophthalmol."},{"key":"93899_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","volume":"4","author":"AM Khanani","year":"2020","unstructured":"Khanani, A. M. et al. SIERRA-AMD: A retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol. Retina 4, 122\u2013133. https:\/\/doi.org\/10.1016\/j.oret.2019.09.009 (2020).","journal-title":"Ophthalmol. Retina"},{"key":"93899_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4103\/tjo.tjo_34_19","volume":"9","author":"BC Yang","year":"2019","unstructured":"Yang, B. C., Chou, T. Y. & Chen, S. N. Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study. Taiwan J. Ophthalmol. 9, 249\u2013254. https:\/\/doi.org\/10.4103\/tjo.tjo_34_19 (2019).","journal-title":"Taiwan J. Ophthalmol."},{"key":"93899_CR35","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim, L. N., Mehta, H., Barthelmes, D., Nguyen, V. & Gillies, M. C. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina 36, 1418\u20131431. https:\/\/doi.org\/10.1097\/IAE.0000000000001142 (2016).","journal-title":"Retina"},{"key":"93899_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude, A. et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease? Prog. Retin Eye Res. 29, 19\u201329. https:\/\/doi.org\/10.1016\/j.preteyeres.2009.10.001 (2010).","journal-title":"Prog. Retin Eye Res."},{"key":"93899_CR37","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh, A. et al. Efficacy and safety of Ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: A randomized clinical trial. JAMA Ophthalmol. 135, 1206\u20131213. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4030 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"93899_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong, T. Y. et al. Efficacy and safety of intravitreal Aflibercept for polypoidal choroidal vasculopathy: Two-year results of the Aflibercept in polypoidal choroidal vasculopathy study. Am. J. Ophthalmol. 204, 80\u201389. https:\/\/doi.org\/10.1016\/j.ajo.2019.02.027 (2019).","journal-title":"Am. J. Ophthalmol."},{"key":"93899_CR39","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1136\/bjophthalmol-2015-308090","volume":"100","author":"D Barthelmes","year":"2016","unstructured":"Barthelmes, D. et al. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br. J. Ophthalmol. 100, 1640\u20131645. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-308090 (2016).","journal-title":"Br. J. Ophthalmol."},{"key":"93899_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.oret.2018.09.001","volume":"3","author":"U Chakravarthy","year":"2019","unstructured":"Chakravarthy, U. et al. Effectiveness of continued ranibizumab therapy in neovascular age-related macular degeneration versus switch to aflibercept: Real world evidence. Ophthalmol. Retina 3, 8\u201315. https:\/\/doi.org\/10.1016\/j.oret.2018.09.001 (2019).","journal-title":"Ophthalmol. Retina"},{"key":"93899_CR41","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash, J. et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U.S.A. 99, 11393\u201311398. https:\/\/doi.org\/10.1073\/pnas.172398299 (2002).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"93899_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","volume":"65","author":"H Mehta","year":"2018","unstructured":"Mehta, H. et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog. Retin Eye Res. 65, 127\u2013146. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.12.002 (2018).","journal-title":"Prog. Retin Eye Res."},{"key":"93899_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/aos.12091","volume":"92","author":"CI Frennesson","year":"2014","unstructured":"Frennesson, C. I. & Nilsson, S. E. A three-year follow-up of ranibizumab treatment of exudative AMD: Impact on the outcome of carrying forward the last acuity observation in drop-outs. Acta Ophthalmol. 92, 216\u2013220. https:\/\/doi.org\/10.1111\/aos.12091 (2014).","journal-title":"Acta Ophthalmol."},{"key":"93899_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ophtha.2012.07.026","volume":"120","author":"R Silva","year":"2013","unstructured":"Silva, R. et al. The SECURE study: Long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 120, 130\u2013139. https:\/\/doi.org\/10.1016\/j.ophtha.2012.07.026 (2013).","journal-title":"Ophthalmology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93899-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93899-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93899-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:27:31Z","timestamp":1670066851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93899-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93899"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93899-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"15 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14623"}}